This study has 2 parts. Part 1 will evaluate the safety and IOP effects of 6 formulations of AGN-210961 ophthalmic solution in the study eye and bimatoprost ophthalmic solution 0.03% in the fellow eye for 7 consecutive days. Part 2 will evaluate the safety and IOP effects of a formulation (to be selected from part 1) of AGN-210961 in both eyes compared to bimatoprost ophthalmic solution 0.03% for 4 weeks.

开始日期2010-06-01

申办/合作机构

Allergan Ltd. (Ireland)

100 项与 Aganepag isopropyl 相关的临床结果

登录后查看更多信息

100 项与 Aganepag isopropyl 相关的转化医学

登录后查看更多信息

100 项与 Aganepag isopropyl 相关的专利（医药）

登录后查看更多信息

项与 Aganepag isopropyl 相关的文献（医药）

2019-04-01·British Journal of Pharmacology2区 · 医学

Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma

2区 · 医学

Review

作者: Brambilla, Stefania ; Impagnatiello, Francesco ; Almirante, Nicoletta ; Kothe, Angela C ; Bastia, Elena ; Bergamini, Michael V W ; Duquesroix, Brigitte

In patients with ocular hypertension or glaucoma, all treatments aim to lower intraocular pressure (IOP) by modulating aqueous humour (AH) production and/or uveoscleral and trabecular meshwork/Schlemm's canal AH drainage. PG analogues are considered to be the ‘gold standard’ treatment and are the most frequently used IOP‐lowering agents. Recent data support an important role for NO in regulating IOP. Thus, novel PG analogues carrying a NO‐donating moiety were recently advanced. Latanoprostene bunod (LBN) and NCX 470, NO‐donating derivatives of latanoprost and bimatoprost, respectively, are examples of such compounds. LBN ophthalmic solution, 0.024% (Vyzulta™), showed greater IOP‐lowering efficacy compared with that of Xalatan® (latanoprost ophthalmic solution, 0.005%) or 0.5% timolol maleate in clinical settings. NCX 470 was found to be more effective than bimatoprost in animal models of ocular hypertension and glaucoma. Selective EP2 receptor agonists (i.e. taprenepag isopropyl, omidenepag isopropyl and aganepag isopropyl) and non‐selective prostanoid receptor agonists (i.e. ONO‐9054, sepetaprost isopropyl) that concomitantly stimulate FP and EP3 receptors have also been shown to hold promise as effective IOP‐lowering agents.Linked ArticlesThis article is part of a themed section on Eicosanoids 35 years from the 1982 Nobel: where are we now? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.8/issuetoc

100 项与 Aganepag isopropyl 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09863	-	-	DB16085

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
开角型青光眼	临床2期	美国	Allergan Ltd. (Ireland)	2010-06-01
青光眼	临床2期	-	Allergan Ltd. (Ireland)	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01110499 (CTgov)	临床2期	开角型青光眼	163	AGN-210961 Formulation 1 (Part 1, AGN-210961 Formulation 1)	夢壓艱繭淵襯觸襯鬱糧(築願鬱襯願膚顧觸蓋廠) = 壓積壓積選築顧觸獵衊觸憲鑰選齋窪鏇餘襯範 (簾艱淵範網構壓憲築壓, 鹹顧廠構餘繭淵餘鬱鏇 ~ 築範築壓壓醖憲構膚範) 更多	-	2014-08-05
				AGN-210961 Formulation 2 (Part 1, AGN-210961 Formulation 2)	夢壓艱繭淵襯觸襯鬱糧(築願鬱襯願膚顧觸蓋廠) = 積繭餘築鬱製築願餘餘觸憲鑰選齋窪鏇餘襯範 (簾艱淵範網構壓憲築壓, 構鏇夢鬱齋鏇製鑰觸夢 ~ 餘製願窪蓋選簾淵膚範) 更多